Applied Genetic Technologies Corporation Stock News

Use these tips for profiting with penny stocks The post Make Money With Penny Stocks in November? 3 Methods to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology co

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology comp

July 7, 2022 at 8:00 AM EDT July 7, 2022 at 8:00 AM EDT

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development a

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript

Applied Genetic (NASDAQ: AGTC ) reported its Q2 earnings results on Monday, February 14, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Applied Genetic missed estimated earnings by 18.42%, reporting … Full story available on Benzinga.com

Applied Genetic press release (AGTC): Q2 GAAP EPS of -$0.45 misses by $0.06.As of December 31, 2021, the Company''s cash and cash equivalents totaled $72.77M.

Companies Reporting Before The Bell • Weber (NYSE: WEBR ) is projected to report quarterly loss at $0.06 per share on revenue of $310.78 million. • Kelly Services (NASDAQ: KELYB ) is expected to report earnings for its fourth quarter. • Westwater Resources (AMEX: WWR ) is likely to report earnings for its fourth quarter. • Scorpio Tankers (NYSE: STNG ) is expected to report quarterly loss at $0.75 per share on revenue of $151.10 million. • Kelly Services (NASDAQ: KELYA ) is expected to report quarterly earnings at $0.28 per share on revenue of $1.30 billion. • Garrett Motion (NASDAQ: GTX ) is projected to report quarterly earnings at $0.19 per share on revenue of $863.00 million. • Applied Genetic (NASDAQ: AGTC ) is expected to report earnings for its second quarter. • Alexander''s (NYSE: ALX ) is projected to report earnings for its fourth quarter. • Acasti Pharma (NASDAQ: ACST ) is estimated to report earnings for its third quarter. • Roivant Sciences (NASDAQ: ROIV ) is estimated to report earnings for its third quarter. • Olink Holding (NASDAQ: OLK ) is expected to report earnings for its fourth quarter. • Treehouse Foods (NYSE: THS ) is likely to report quarterly earnings at $0.09 per share on revenue of $1.12 billion. • Hawaiian Electric Indus (NYSE: HE ) is expected to report quarterly earnings at $0.42 per share on revenue of $681.34 million.

Applied Genetic Technologies (NASDAQ:AGTC) is scheduled to announce Q2 earnings results on Monday, Feb. 14, before market open.The consensus EPS Estimate is -$0.39.

New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry A ge-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market. DelveInsight''s '' Dry Age-related Macular Degeneration Pipeline Insight 2021 '' report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain. Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report DelveInsight''s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and

Applied Genetic Technologies Corp (AGTC) shares closed today at 1.1% above its 52 week low of $1.76, giving the company a market cap of $76M. The stock is currently down 6.3% year-to-date, down 62.3% over the past 12 months, and down 81.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 27.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.7% lower than its 5-day moving average, 7.6% lower than its 20-day moving average, and 31.2% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -6896.3% The company's stock price performance over the past 12 months lags the peer average by 34.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Applied Genetic Technologies Corp (AGTC) shares closed today at 0.5% above its 52 week low of $1.82, giving the company a market cap of $78M. The stock is currently down 3.7% year-to-date, down 57.8% over the past 12 months, and down 81.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 29.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 717.6% The company's stock price performance over the past 12 months lags the peer average by 28.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.